GZD824 strongly suppresses FGFR1–3 and effectively overcomes FGFR1‐V561F/M and other mutant resistance in vitro and in vivo, and may serve as a novel drug in clinical trials of cancer therapy. Here, FGFR1 is linked to cancer.